Jordan Fenlon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jordan Fenlon has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Gita Suneja
Department of Radiation Oncology, University of Utah School of Medicine, Huntsman Cancer Institute , Salt Lake City, Utah
6 shared publications - Adam Mitchell Spivak
Division of Infectious Diseases, Department of Internal Medicine, Huntsman Cancer Institute – University of Utah, Salt Lake City, Utah
5 shared publications - Alex C. Soupir
Moffitt Cancer Center
5 shared publications - Anna E. Coghill
Cancer Epidemiology Program, Division of Population Sciences, H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA
5 shared publications - Beatrice S. Knudsen
University of Utah
5 shared publications - Carlos Moran Segura
Advanced Analytical and Digital Laboratory, Moffitt Cancer Center, Tampa, Florida
5 shared publications
Latest Publications
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from Human Immunodeficiency Virus–Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers
Supplemental Table 2: Number of Tumor Samples, and Number (%) Individual Patients, with Tissue Staining Results Available, by Immune Marker and Cancer Type.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from Human Immunodeficiency Virus–Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers
Supplemental Table 2: Number of Tumor Samples, and Number (%) Individual Patients, with Tissue Staining Results Available, by Immune Marker and Cancer Type.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Human Immunodeficiency Virus–Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers
Supplemental Figure 1: Percentage of tumor cells staining positive for immune markers, and age and race-adjusted associations (ORs [95% CI]) between tumor immune marker staining abundance and patient HIV status, by cancer type. All immune markers associations are shown.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Human Immunodeficiency Virus–Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers
Supplemental Figure 1: Percentage of tumor cells staining positive for immune markers, and age and race-adjusted associations (ORs [95% CI]) between tumor immune marker staining abundance and patient HIV status, by cancer type. All immune markers associations are shown.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Human Immunodeficiency Virus–Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers
Supplemental Table 1: Number of Study Specimens by HIV Status, Cancer Type, and Source.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Human Immunodeficiency Virus–Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers
Supplemental Table 1: Number of Study Specimens by HIV Status, Cancer Type, and Source.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Data from Human Immunodeficiency Virus–Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers
Background:Cancer outcomes in people living with human immunodeficiency virus (PWH) may be driven in part by a distinct tumor microenvironment (TME) for cancers that develop in the setting of persistent immune dysfunction.Methods:Tumor samples from PWH were retrospectively obtained from the AIDS Cancer Specimen Resource, Moffitt Cancer Center, and Huntsman Cancer Institute. Staining of 22 different tumor immune markers was compared between PWH and cancer and patients diagnosed with the same cancer type but without human immunodeficiency virus.Results:A total of 292 samples were analyzed, with 51 samples obtained from PWH (lung cancer = 17; breast cancer = 14; and prostate cancer = 20). Cells positive for PD-1 were observed more frequently in PWH and lung cancer [OR, 1.88; 95% confidence interval (CI), 1.02–3.45], whereas CD11b+ cells were observed less frequently (OR, 0.4; 95% CI, 0.17–0.93). Three immune markers showed higher abundance in PWH and breast cancer, including PD-L1 (OR, 3.24; 95% CI, 1.52–6.91), CD14 (OR, 3.37; 95% CI, 1.14–10.0), and FOXP3 (OR, 1.91; 95% CI, 1.03–3.53). In PWH and prostate cancer, the abundance of five immune markers was higher, including PD-L1 (OR, 5.94; 95% CI, 3.77–9.34), whereas three markers had lower abundance including CD14 (OR, 0.40; 95% CI, 0.22–0.74), as well as CD16 and CD11c.Conclusions:This pilot study showed that differences in the TME exist for PWH diagnosed with age-related non-AIDS–defining cancers. Future work evaluating TME differences in relation to clinical endpoints is needed.Impact:Findings are consistent with the hypothesis of altered tumorigenesis for cancers developing in an environment of immunosuppression.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Human Immunodeficiency Virus–Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers
Background:Cancer outcomes in people living with human immunodeficiency virus (PWH) may be driven in part by a distinct tumor microenvironment (TME) for cancers that develop in the setting of persistent immune dysfunction.Methods:Tumor samples from PWH were retrospectively obtained from the AIDS Cancer Specimen Resource, Moffitt Cancer Center, and Huntsman Cancer Institute. Staining of 22 different tumor immune markers was compared between PWH and cancer and patients diagnosed with the same cancer type but without human immunodeficiency virus.Results:A total of 292 samples were analyzed, with 51 samples obtained from PWH (lung cancer = 17; breast cancer = 14; and prostate cancer = 20). Cells positive for PD-1 were observed more frequently in PWH and lung cancer [OR, 1.88; 95% confidence interval (CI), 1.02–3.45], whereas CD11b+ cells were observed less frequently (OR, 0.4; 95% CI, 0.17–0.93). Three immune markers showed higher abundance in PWH and breast cancer, including PD-L1 (OR, 3.24; 95% CI, 1.52–6.91), CD14 (OR, 3.37; 95% CI, 1.14–10.0), and FOXP3 (OR, 1.91; 95% CI, 1.03–3.53). In PWH and prostate cancer, the abundance of five immune markers was higher, including PD-L1 (OR, 5.94; 95% CI, 3.77–9.34), whereas three markers had lower abundance including CD14 (OR, 0.40; 95% CI, 0.22–0.74), as well as CD16 and CD11c.Conclusions:This pilot study showed that differences in the TME exist for PWH diagnosed with age-related non-AIDS–defining cancers. Future work evaluating TME differences in relation to clinical endpoints is needed.Impact:Findings are consistent with the hypothesis of altered tumorigenesis for cancers developing in an environment of immunosuppression.
- 4 April 2025
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34 (6) , 860-867
Human Immunodeficiency Virus–Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers
Background: Cancer outcomes in people living with human immunodeficiency virus (PWH) may be driven in part by a distinct tumor microenvironment (TME) for cancers that develop in the setting of persistent immune dysfunction. Methods: Tumor samples from PWH were retrospectively obtained from the AIDS Cancer Specimen Resource, Moffitt Cancer Center, and Huntsman Cancer Institute. Staining of 22 different tumor immune markers was compared between PWH and cancer and patients diagnosed with the same cancer type but without human immunodeficiency virus. Results: A total of 292 samples were analyzed, with 51 samples obtained from PWH (lung cancer = 17; breast cancer = 14; and prostate cancer = 20). Cells positive for PD-1 were observed more frequently in PWH and lung cancer [OR, 1.88; 95% confidence interval (CI), 1.02–3.45], whereas CD11b+ cells were observed less frequently (OR, 0.4; 95% CI, 0.17–0.93). Three immune markers showed higher abundance in PWH and breast cancer, including PD-L1 (OR, 3.24; 95% CI, 1.52–6.91), CD14 (OR, 3.37; 95% CI, 1.14–10.0), and FOXP3 (OR, 1.91; 95% CI, 1.03–3.53). In PWH and prostate cancer, the abundance of five immune markers was higher, including PD-L1 (OR, 5.94; 95% CI, 3.77–9.34), whereas three markers had lower abundance including CD14 (OR, 0.40; 95% CI, 0.22–0.74), as well as CD16 and CD11c. Conclusions: This pilot study showed that differences in the TME exist for PWH diagnosed with age-related non-AIDS–defining cancers. Future work evaluating TME differences in relation to clinical endpoints is needed. Impact: Findings are consistent with the hypothesis of altered tumorigenesis for cancers developing in an environment of immunosuppression.
- 4 April 2025
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34 (6) , 860-867
Human Immunodeficiency Virus–Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers
Background: Cancer outcomes in people living with human immunodeficiency virus (PWH) may be driven in part by a distinct tumor microenvironment (TME) for cancers that develop in the setting of persistent immune dysfunction. Methods: Tumor samples from PWH were retrospectively obtained from the AIDS Cancer Specimen Resource, Moffitt Cancer Center, and Huntsman Cancer Institute. Staining of 22 different tumor immune markers was compared between PWH and cancer and patients diagnosed with the same cancer type but without human immunodeficiency virus. Results: A total of 292 samples were analyzed, with 51 samples obtained from PWH (lung cancer = 17; breast cancer = 14; and prostate cancer = 20). Cells positive for PD-1 were observed more frequently in PWH and lung cancer [OR, 1.88; 95% confidence interval (CI), 1.02–3.45], whereas CD11b+ cells were observed less frequently (OR, 0.4; 95% CI, 0.17–0.93). Three immune markers showed higher abundance in PWH and breast cancer, including PD-L1 (OR, 3.24; 95% CI, 1.52–6.91), CD14 (OR, 3.37; 95% CI, 1.14–10.0), and FOXP3 (OR, 1.91; 95% CI, 1.03–3.53). In PWH and prostate cancer, the abundance of five immune markers was higher, including PD-L1 (OR, 5.94; 95% CI, 3.77–9.34), whereas three markers had lower abundance including CD14 (OR, 0.40; 95% CI, 0.22–0.74), as well as CD16 and CD11c. Conclusions: This pilot study showed that differences in the TME exist for PWH diagnosed with age-related non-AIDS–defining cancers. Future work evaluating TME differences in relation to clinical endpoints is needed. Impact: Findings are consistent with the hypothesis of altered tumorigenesis for cancers developing in an environment of immunosuppression.
- 21 November 2022
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 64 (2) , 356-363
Evaluating patterns of care for early-stage low-grade follicular lymphoma in the rituximab era
Radiotherapy (RT) utilization for early-stage, low-grade follicular lymphoma (FL) is low despite treatment guideline recommendations. We compare treatment trends for early-stage FL in the era of involved-site RT and rituximab. We identified 11,645 patients in the National Cancer Database (NCDB) with stage I–II, grade 1–2 nodal or extranodal FL diagnosed 2011–2017, with median follow-up of 44 months. From 2011 to 2017, RT utilization rates decreased from 33.4% to 22.4%, observation decreased from 65.3% to 49.7%, chemoimmunotherapy increased from 0.5% to 15.0%, immuno-monotherapy increased from 0.6% to 10.2%, and RT + systemic therapy increased from 0.6% to 2.5%. RT utilization remains low in the involved-site RT and rituximab era.
- 21 November 2022
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 64 (2) , 356-363
Evaluating patterns of care for early-stage low-grade follicular lymphoma in the rituximab era
Radiotherapy (RT) utilization for early-stage, low-grade follicular lymphoma (FL) is low despite treatment guideline recommendations. We compare treatment trends for early-stage FL in the era of involved-site RT and rituximab. We identified 11,645 patients in the National Cancer Database (NCDB) with stage I–II, grade 1–2 nodal or extranodal FL diagnosed 2011–2017, with median follow-up of 44 months. From 2011 to 2017, RT utilization rates decreased from 33.4% to 22.4%, observation decreased from 65.3% to 49.7%, chemoimmunotherapy increased from 0.5% to 15.0%, immuno-monotherapy increased from 0.6% to 10.2%, and RT + systemic therapy increased from 0.6% to 2.5%. RT utilization remains low in the involved-site RT and rituximab era.
- 22 October 2022
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 114 (3) , e219
Dosimetrically Correlating the Acute Effect of Bone Radiation on Anemia in Men with Intact Prostate Cancer
- 22 October 2022
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 114 (3) , e219
Dosimetrically Correlating the Acute Effect of Bone Radiation on Anemia in Men with Intact Prostate Cancer
- 13 August 2022
- Published by Elsevier in Brachytherapy
- Vol. 21 (6) , 764-768
Radical trachelectomy and adjuvant vaginal brachytherapy to preserve fertility in pediatric cervical adenocarcinoma
- 13 August 2022
- Published by Elsevier in Brachytherapy
- Vol. 21 (6) , 764-768
Radical trachelectomy and adjuvant vaginal brachytherapy to preserve fertility in pediatric cervical adenocarcinoma
- 7 March 2022
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 32 (3) , 429-435
Gynecological radiotherapy in people living with human immunodeficiency virus: a semi-systematic literature review
Appropriate diagnosis and treatment of gynecological cancers in people living with human immunodeficiency virus (HIV) remains a clinical challenge given rapid changes in both HIV and cancer management and a lack of prospective clinical trial data inclusive of the HIV population. A semi-systematic literature review was performed to identify published studies addressing risk factors, screening, treatment efficacy, treatment toxicity, and prognosis for people living with HIV diagnosed with gynecological malignancies, with a focus on radiotherapy and cervical cancer, given the relative paucity of literature on uterine, ovarian, and vulvovaginal cancers in people living with HIV. People living with HIV are more likely to be co-infected with human papilloma virus and more likely to develop human papilloma virus-associated malignancies. People living with HIV are less likely to receive cancer treatment compared with HIV-uninfected cancer patients, even after adjusting for differences in clinical features and sociodemographic variables. The literature on cervical cancer outcomes is mixed, with some studies demonstrating that people living with HIV have inferior treatment tolerability, response rates, and survival following chemoradiotherapy, and others showing no difference in these outcomes, particularly in patients receiving antiretroviral therapy. Importantly, even in the series showing inferior outcomes in people living with HIV, there were long-term survivors after administration of curative therapy. Consistent with published cancer management guidelines, people living with HIV diagnosed with gynecological cancers should be treated with standard cancer therapy. Co-management with the patient’s HIV specialist is critical to avoid overlapping toxicities and provide optimal supportive care. The morbidity and mortality caused by gynecologic cancers in this population can be mitigated by early diagnosis, appropriate treatment delivery including inclusion of people with HIV in cancer clinical trials, and diligent HIV management.
- 7 March 2022
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 32 (3) , 429-435
Gynecological radiotherapy in people living with human immunodeficiency virus: a semi-systematic literature review
Appropriate diagnosis and treatment of gynecological cancers in people living with human immunodeficiency virus (HIV) remains a clinical challenge given rapid changes in both HIV and cancer management and a lack of prospective clinical trial data inclusive of the HIV population. A semi-systematic literature review was performed to identify published studies addressing risk factors, screening, treatment efficacy, treatment toxicity, and prognosis for people living with HIV diagnosed with gynecological malignancies, with a focus on radiotherapy and cervical cancer, given the relative paucity of literature on uterine, ovarian, and vulvovaginal cancers in people living with HIV. People living with HIV are more likely to be co-infected with human papilloma virus and more likely to develop human papilloma virus-associated malignancies. People living with HIV are less likely to receive cancer treatment compared with HIV-uninfected cancer patients, even after adjusting for differences in clinical features and sociodemographic variables. The literature on cervical cancer outcomes is mixed, with some studies demonstrating that people living with HIV have inferior treatment tolerability, response rates, and survival following chemoradiotherapy, and others showing no difference in these outcomes, particularly in patients receiving antiretroviral therapy. Importantly, even in the series showing inferior outcomes in people living with HIV, there were long-term survivors after administration of curative therapy. Consistent with published cancer management guidelines, people living with HIV diagnosed with gynecological cancers should be treated with standard cancer therapy. Co-management with the patient’s HIV specialist is critical to avoid overlapping toxicities and provide optimal supportive care. The morbidity and mortality caused by gynecologic cancers in this population can be mitigated by early diagnosis, appropriate treatment delivery including inclusion of people with HIV in cancer clinical trials, and diligent HIV management.